A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out and it may have to file for bankruptcy protection. Shares in the South ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

Shortly after claiming FDA approval for its Filspari therapy for rare kidney disease IgA Nephropathy (IgAN), Travere Therapeutics has said it will price the drug at a discount to a recently-approved ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

From chip giant NVIDIA agreeing a $2 billion partnership with AI cloud provider Nebius, to Roche ramping up its investment in ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

For years, conversations about artificial intelligence (AI) in life sciences have alternated between hype and hesitation.

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

New guidance from reimbursement authority NICE has recommended Rystiggo (rozanolixizumab) for people with gMG who test ...